var data={"title":"Vismodegib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vismodegib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/495570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vismodegib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vismodegib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765898\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Embryofetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vismodegib can cause embryofetal death or severe birth defects when administered to a pregnant woman. Vismodegib is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Verify pregnancy status of females of reproductive potential within 7 days prior to initiating vismodegib therapy. Advise females of reproductive potential to use effective contraception during and after vismodegib therapy. Advise males of the potential risk of vismodegib exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential. Advise pregnant women of the potential risks to a fetus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13797019\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Erivedge</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21313108\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Erivedge</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13755425\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Hedgehog Pathway Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765936\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Basal cell carcinoma, metastatic or locally advanced:</b> Oral: 150 mg once daily until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Missed doses:</i> If a dose is missed, do not make up; resume dosing with the next scheduled dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765938\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765937\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44479435\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">In clinical trials, no dosage reductions were allowed for toxicities, however, treatment interruptions up to 4 to 8 weeks were allowed for toxicity recovery (Basset-Seguin 2015; Sekulic 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13797020\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erivedge: 150 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765904\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765903\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;\">\n      <i>US:</i> Available at specialty pharmacies through the Erivedge Access Solutions program. Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at <a target=\"_blank\" href=\"http://www.erivedgeaccesssolutions.com&amp;token=4j9DLh+AvLS5qZ3kr+bsqoRV1wGLKiAdKzw/LsrKQcKYQTdeFCgeeg9femPsbvy0&amp;TOPIC_ID=17142\" target=\"_blank\">www.ErivedgeAccessSolutions.com</a></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canada:</i> Available through a controlled distribution program called Erivedge Pregnancy Prevention Program (EPPP). Registration with the program is required for participating prescribers and pharmacies. Patients must also be registered with the program and meet all necessary requirements to receive vismodegib. Consult product monograph for detailed information regarding program requirements. Further information may also be obtained at 1-888-748-8926 or at <a target=\"_blank\" href=\"http://www.erivedge.ca&amp;token=4j9DLh+AvLS5qZ3kr+bsqqeJSAe87HHyTLjWJIjdWMI=&amp;TOPIC_ID=17142\" target=\"_blank\">www.erivedge.ca</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765901\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203388s011lbl.pdf#page=12&amp;token=oQI3bzod4zi6SIJWYchoIo/eergPPEXqWXo+RK3+1cxedFmF1feHtQKPeHqcYh/mHYSThl/cTcW87DmjrAatOaHXiSVfUEAiGr48V2mBUGZga5KQvaXGgiTGLmM7dOeC&amp;TOPIC_ID=17142\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203388s011lbl.pdf#page=12</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765940\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be taken with or without food. Swallow capsules whole; do not open or crush.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104603\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13753724\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Basal cell carcinoma, metastatic or locally advanced:</b> Treatment of metastatic basal cell carcinoma, or locally-advanced basal cell carcinoma that has recurred following surgery or in patients who are not candidates for surgery, and not candidates for radiation therapy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765899\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vismodegib may be confused with sonidegib, vandetanib, vemurafenib, venetoclax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765912\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (64%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea (&le;30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (55%), weight loss (45%), nausea (30%), diarrhea (29%), decreased appetite (25%), constipation (21%), vomiting (14%), ageusia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (72%), arthralgia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia, hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Azotemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765909\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to vismodegib or any component of the formulation; pregnancy or females at risk of becoming pregnant; breast-feeding; male patients or female patients of childbearing potential who do not comply with the Erivedge Pregnancy Prevention Program; children and adolescents &lt;18 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765910\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Amenorrhea: Amenorrhea was observed in women of reproductive potential; it is unknown if this is reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite may occur (usually grade 1 or 2).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Premature fusion of the epiphyses has been reported in pediatric patients exposed to vismodegib; the fusion progressed after vismodegib discontinuation in some cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warnings]: May result in severe birth defects or embryo-fetal death. Teratogenic effects (severe midline defects, missing digits, and other irreversible malformations), embryotoxic, and fetotoxic events were observed in animal reproduction studies. Verify pregnancy status (in females of reproductive potential) within 7 days prior to initiating treatment and advise patients (female and male) of the risk of birth defects, the need for contraception and risk of exposure through semen and to use condoms with a pregnant partner or a female partner of childbearing potential.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood donations: Advise patients not to donate blood or blood products during vismodegib treatment and for at least 24 months after the last vismodegib dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Semen donations: Vismodegib is present in semen, although the amount of drug in semen that may cause embryotoxicity and/or fetotoxicity is not known. Advise male patients not to donate sperm during vismodegib treatment and for 3 months after the last vismodegib dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Toxicity duration: In a study of vismodegib in patients with basal cell nevus syndrome (not an approved use), with discontinuation of vismodegib treatment, taste alteration and muscle cramps abated within 1 month, and scalp and body hair began to regrow within 3 months (Tang 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13769106\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13769104\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17142&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765906\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: May result in severe birth defects or embryo-fetal death. Teratogenic effects (severe midline defects, missing digits, and other irreversible malformations), embryotoxic, and fetotoxic events were observed in animal reproduction studies</b> when administered in doses less than the normal human dose. Based on its mechanism of action adverse effects on pregnancy would be expected. <b>[US Boxed Warning]: Verify pregnancy status (in females of reproductive potential) within 7 days prior to initiating treatment and advise patients (female and male) of the risk of birth defects, the need for contraception and risk of exposure through semen and to use condoms with a pregnant partner or a female partner of childbearing potential.</b> In females of childbearing potential, obtain pregnancy test within 7 days prior to treatment initiation; after the negative pregnancy test, initiate highly effective contraception prior to the first vismodegib dose and continue during treatment and for 24 months after the final dose. During treatment (including treatment interruptions) and for 3 months after treatment, male patients should not donate sperm and should use condoms with spermicide (even after vasectomy) if their partner is of childbearing potential.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to vismodegib during pregnancy (directly or via seminal fluid) are encouraged to participate in the Erivedge Pregnancy Pharmacovigilance program by contacting the Genentech Adverse Event Line (1-888-835-2555). Pregnancies occurring during or within 7 months after treatment should be reported to the Genentech Adverse Event Line.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In Canada, vismodegib is available only through a controlled distribution program (Erivedge Pregnancy Prevention Program). Female and male patients of reproductive potential must be registered with the program and comply with all requirements. Females of childbearing potential should use 2 simultaneous forms of effective contraception beginning at least 4 weeks prior to treatment initiation, during treatment (including treatment interruptions), and for 24 months after discontinuation. Pregnancy testing should be performed within 7 days prior to treatment initiation, monthly during treatment (including treatment interruptions), and for 24 months after discontinuation. For females of child bearing potential, a new prescription is required each month to allow for monthly pregnancy testing. During treatment (including treatment interruptions) and for 2 months after treatment, male patients should not donate sperm and should use condoms with spermicide (even after vasectomy) if their partner is of childbearing potential. Any suspected exposure (directly or via seminal fluid) during pregnancy should be immediately reported to the Erivedge Pregnancy Prevention Program at 1-888-748-8926.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765908\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if vismodegib is excreted in breast milk. Due to the potential for serious adverse reactions in the breast-feeding infant, breast-feeding is not recommended by the manufacturer during therapy and for 24 months after the last vismodegib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765942\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pregnancy test within 1 week prior to treatment initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765924\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Basal cell cancer is associated with mutations in Hedgehog pathway components. Hedgehog regulates cell growth and differentiation in embryogenesis; while generally not active in adult tissue, Hedgehog mutations associated with basal cell cancer can activate the pathway resulting in unrestricted proliferation of skin basal cells. Vismodegib is a selective Hedgehog pathway inhibitor which binds to and inhibits Smoothened homologue (SMO), the transmembrane protein involved in Hedgehog signal transduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13765926\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 16.4 to 26.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: In a small pharmacokinetic study, the average vismodegib concentration in semen was 6.5% of the average steady state plasma concentration on day 8</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%; primarily to serum albumin and alpha<sub>1</sub> acid glycoprotein (AAG)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized by oxidation, glucuronidation, and pyridine ring cleavage, although &gt;98% of circulating components are as the parent drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~32%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: Continuous daily dosing: ~4 days; Single dose: ~12 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~2.4 days (Graham 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (82%); urine (4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322930\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Erivedge Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (28): $12,920.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671727\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Edivedzh (UA);</li>\n      <li>Erivedge (AR, AT, AU, BB, CH, CL, CR, CU, CY, CZ, DE, DK, EE, FR, GB, GT, HK, HN, HR, HU, IE, IL, IS, KR, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PL, PT, QA, RO, SE, SG, SI, SK, SV, TH, TR);</li>\n      <li>WErivedge (DO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncol</i>. 2015;16(6):729-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/25981813/pubmed\" target=\"_blank\" id=\"25981813\">25981813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erivedge (vismodegib) [prescribing information]. South San Francisco, CA: Genentech USA; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erivedge (vismodegib) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham RA, Lum BL, Cheeti S, et al, &ldquo;Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Solid Tumors: The Role of Alpha-1-Acid Glycoprotein Binding,&rdquo; <i>Clin Cancer Res</i>, 2011, 17(8):2512-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/21300760/pubmed\" target=\"_blank\" id=\"21300760\">21300760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iarrobino A, Messina JL, Kudchadkar R, et al, &ldquo;Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib,&rdquo; <i>J Am Acad Dermatol</i>, 2013, 69(1):e33-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/23768306/pubmed\" target=\"_blank\" id=\"23768306\">23768306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorusso PM, Jimeno A, Dy G, et al, &ldquo;Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Solid Tumors,&rdquo; <i>Clin Cancer Res</i>, 2011, 17(17):5774-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/21753154/pubmed\" target=\"_blank\" id=\"21753154\">21753154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LoRusso PM, Rudin CM, Reddy JC, et al, &ldquo;Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Refractory, Locally Advanced or Metastatic Solid Tumors,&rdquo; <i>Clin Cancer Res</i>, 2011, 17(8):2502-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/21300762/pubmed\" target=\"_blank\" id=\"21300762\">21300762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Low JA and de Sauvage FJ, &ldquo;Clinical Experience With Hedgehog Pathway Inhibitors,&rdquo; <i>J Clin Oncol</i>, 2010, 28(36):5321-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/21041712/pubmed\" target=\"_blank\" id=\"21041712\">21041712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudin CM, Hann CL, Laterra J, et al, &ldquo;Treatment of Medulloblastoma With Hedgehog Pathway Inhibitor GDC-0449,&rdquo; <i>N Engl J Med</i>, 2009, 361(12):1173-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/19726761/pubmed\" target=\"_blank\" id=\"19726761\">19726761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sekulic A, Migden M, Oro AE, et al, &ldquo;Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma,&rdquo; <i>New Engl J Med</i>, 2012, 366(23):2171-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/22670903/pubmed\" target=\"_blank\" id=\"22670903\">22670903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma MR, Karrison TG, Kell B, et al, &ldquo;Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients,&rdquo; <i>Clin Cancer Res</i>, 2013, 19(11):3059-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/23553850/pubmed\" target=\"_blank\" id=\"23553850\">23553850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al, &ldquo;Inhibiting the Hedgehog Pathway in Patients With the Basal-Cell Nevus Syndrome,&rdquo; <i>New Engl J Med</i>, 2012, 366(23):2180-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/22670904/pubmed\" target=\"_blank\" id=\"22670904\">22670904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Von Hoff DD, LoRusso PM, Rudin CM, et al, &ldquo;Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,&rdquo; <i>N Engl J Med</i>, 2009, 361(12):1164-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/19726763/pubmed\" target=\"_blank\" id=\"19726763\">19726763</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17142 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13765898\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13797019\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21313108\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13755425\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13765936\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13765938\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13765937\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F44479435\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13797020\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13765904\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F13765903\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13765901\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13765940\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104603\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13753724\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13765899\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13765912\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13765909\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13765910\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13769106\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13769104\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13765906\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13765908\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13765942\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13765924\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13765926\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322930\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671727\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17142|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vismodegib-patient-drug-information\" class=\"drug drug_patient\">Vismodegib: Patient drug information</a></li></ul></div></div>","javascript":null}